Northwest Biotherapeutics, Inc.
NWBO
$0.23
$0.000.09%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 52.67% | -65.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 52.67% | -65.07% | |||
| Cost of Revenue | 0.27% | -11.03% | |||
| Gross Profit | 0.67% | 8.49% | |||
| SG&A Expenses | -5.48% | -19.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.62% | -15.70% | |||
| Operating Income | 3.11% | 14.63% | |||
| Income Before Tax | -74.46% | 20.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -74.46% | 20.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -74.46% | 20.50% | |||
| EBIT | 3.11% | 14.63% | |||
| EBITDA | 3.20% | 15.10% | |||
| EPS Basic | -63.96% | 22.92% | |||
| Normalized Basic EPS | -64.81% | 25.00% | |||
| EPS Diluted | -80.18% | 22.92% | |||
| Normalized Diluted EPS | -64.81% | 25.00% | |||
| Average Basic Shares Outstanding | 3.75% | 5.79% | |||
| Average Diluted Shares Outstanding | 3.75% | 5.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||